Abstract:Background: Anaplastic thyroid carcinoma (ATC) is recognized as the most aggressive and malignant form of thyroid cancer, underscoring the critical need for effective therapeutic strategies to curb its progression and improve patient prognosis. Halofuginone (HF), a derivative of febrifugine, has displayed antitumor properties across various cancer types. However, there is a paucity of published research focused on the potential of HF to enhance the clinical efficacy of treating ATC. Objective: In this study, we thoroughly investigated the antitumor effects and mechanisms of HF in ATC, aiming to discover lead compounds for treating ATC and reveal novel therapeutic targets for ATC tumors. Methods: A series of assays, including CCK8, colony formation, tumor xenograft models, and ATC tumor organoid experiments, were conducted to evaluate the anticancer properties of HF both in vitro and in vivo. Techniques such as drug affinity responsive target stability (DARTS), western blot, immunofluorescence, and immunohistochemistry were employed to pinpoint HF target proteins within ATC. Furthermore, we harnessed the GEPIA and GEO databases and performed immunohistochemistry to validate the therapeutic potential of the glutamyl-prolyl-tRNA-synthetase (EPRS)- activating transcription factor 4 (ATF4)- type I collagen (COLI) pathway axis in the context of ATC. The study also incorporated RNA sequencing analysis, confocal imaging, and flow cytometry to delve into the molecular mechanisms of HF in ATC. Results: HF exhibited a substantial inhibitory impact on cell proliferation in vitro and on tumor growth in vivo. The DARTS results highlighted HF's influence on EPRS within ATC cells, triggering an amino acid starvation response (AASR) by suppressing EPRS expression, consequently leading to a reduction in COLI expression in ATC cells. The introduction of proline mitigated the effect of HF on ATF4 and COLI expression, indicating that the EPRS-ATF4-COLI pathway axis was a focal target of HF in ATC. Analysis of the expression levels of the EPRS, ATF4, and COLI proteins in thyroid tumors, along with an examination of the relationship between COLI expression and thyroid tumor stage, revealed that HF significantly inhibited the growth of ATC tumor organoids, demonstrating the therapeutic potential of targeting the EPRS-ATF4-COLI pathway axis in ATC. RNA sequencing analysis revealed significant differences in the pathways associated with metastasis and apoptosis between control and HF-treated cells. Transwell assays and flow cytometry experiments provided evidence of the capacity of HF to impede cell migration and induce apoptosis in ATC cells. Furthermore, HF hindered cell metastasis by suppressing the epithelial-mesenchymal transition (EMT) pathway, acting through the inhibition of FAK-AKT-NF-κB/Wnt-β-catenin signaling and restraining angiogenesis via the VEGF pathway. HF also promoted apoptosis through the mitochondrial apoptotic pathway. Conclusion: This study provided inaugural evidence suggesting that HF could emerge as a promising therapeutic agent for the treatment of ATC. The EPRS-ATF4-COLI pathway axis stood out as a prospective biomarker and therapeutic target for ATC.

Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.

Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma

Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma*

Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer

Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma Via Integrated Bioinformatics Analysis.

Advances in targeted therapy for anaplastic thyroid carcinoma

The Differences of Regulatory Networks Between Papillary and Anaplastic Thyroid Carcinoma: an Integrative Transcriptomics Study

Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma

Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy

Identification of the Transforming Strn-Alk Fusion As A Potential Therapeutic Target in the Aggressive Forms of Thyroid Cancer

Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma

KAT5 Inhibitor NU9056 Suppresses Anaplastic Thyroid Carcinoma Progression through c-Myc/miR-202 Pathway

Targetable Treatment Resistance in Thyroid Cancer with Clonal Hematopoiesis

Abstract 3068: CREBBP/EP300 Disruption Promotes Tumor Progression and Confers Synthetic Lethality in Anaplastic Thyroid Cancers

A Distinct Tumor Microenvironment Makes Anaplastic Thyroid Cancer More Lethal but Immunotherapy Sensitive Than Papillary Thyroid Cancer

The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies

The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy

REGγ Ablation Impedes Dedifferentiation of Anaplastic Thyroid Carcinoma and Accentuates Radio-Therapeutic Response by Regulating the Smad7-TGF-β Pathway.

Bioinformatics Analysis of Key Genes and Latent Pathway Interactions Based on the Anaplastic Thyroid Carcinoma Gene Expression Profile.

Targeting Glycogen Metabolism as a Novel Therapeutic Approach in Anaplastic Thyroid Cancer

Weighted Gene Co-Expression Network Reveals Driver Genes Contributing to Phenotypes of Anaplastic Thyroid Carcinoma and Immune Checkpoint Identification for Therapeutic Targets.